Human papillomavirus (HPV) Associated Cancer Pipeline Review, H2 2012


#153021

52pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Human papillomavirus (HPV) Associated Cancer Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Human papillomavirus (HPV) Associated Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Human papillomavirus (HPV) Associated Cancer. 

Human papillomavirus (HPV) Associated Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Human papillomavirus (HPV) Associated Cancer.
  • A review of the Human papillomavirus (HPV) Associated Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Human papillomavirus (HPV) Associated Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Human papillomavirus (HPV) Associated Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Human papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Human papillomavirus (HPV) Associated Cancer Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Human papillomavirus (HPV) Associated Cancer 8
Human papillomavirus (HPV) Associated Cancer Therapeutics under Development by Companies 10
Human papillomavirus (HPV) Associated Cancer Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Human papillomavirus (HPV) Associated Cancer Therapeutics – Products under Development by Companies 17
Human papillomavirus (HPV) Associated Cancer Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Human papillomavirus (HPV) Associated Cancer Therapeutics Development 19
Merck & Co., Inc. 19
Curis, Inc. 20
Transgene SA 21
Prima BioMed Limited 22
Antigen Express, Inc. 23
Etubics Corporation 24
Sirnaomics, Inc. 25
Cancer Therapeutics CRC Pty Ltd 26
EyeGene, Inc. 27
Coridon Pty Ltd 28
Human papillomavirus (HPV) Associated Cancer – Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
V-503 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
TG-4001 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
HPV-Head and Neck Cancer Vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CUDC-101 + Cisplatin + Radiation Therapy - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
AEH-10p - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
P16_37-63 Vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
EG-HPV - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Human Papillomavirus Vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
STP911 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Drug Targeting E6AP - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
HPV-16 E6 peptides + Candin - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
HPV Vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Detox + Cyclophosphamide - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Human papillomavirus (HPV) Associated Cancer Therapeutics – Drug Profile Updates 49
Human papillomavirus (HPV) Associated Cancer – Product Development Milestones 50
Featured News & Press Releases 50
Sep 04, 2012: Republic Of Uganda And Merck Launch Cervical Cancer Vaccination Program With Gardasil 50
Feb 28, 2012: Coridon To Develop New HPV Therapeutic Vaccine 50

Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

Number of Products Under Development for Human papillomavirus (HPV) Associated Cancer, H2 2012 8
Products under Development for Human papillomavirus (HPV) Associated Cancer Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Merck & Co., Inc., H2 2012 19
Curis, Inc., H2 2012 20
Transgene SA, H2 2012 21
Prima BioMed Limited, H2 2012 22
Antigen Express, Inc., H2 2012 23
Etubics Corporation, H2 2012 24
Sirnaomics, Inc., H2 2012 25
Cancer Therapeutics CRC Pty Ltd, H2 2012 26
EyeGene, Inc., H2 2012 27
Coridon Pty Ltd, H2 2012 28
Assessment by Monotherapy Products, H2 2012 29
Assessment by Combination Products, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 34
Human papillomavirus (HPV) Associated Cancer Therapeutics Drug Profile Updates 49
Number of Products under Development for Human papillomavirus (HPV) Associated Cancer, H2 2012 8
Products under Development for Human papillomavirus (HPV) Associated Cancer Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Discovery and Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 29
Assessment by Combination Products, H2 2012 30
Assessment by Route of Administration, H2 2012 31
Assessment by Stage and Route of Administration, H2 2012 32
Assessment by Molecule Type, H2 2012 33
Assessment by Stage and Molecule Type, H2 2012 34